Compare Merck & Co., Inc. (MRK) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Merck & Co., Inc. trades at $148.11 (market cap $366.28B), while Direxion Daily TSLA Bull 2X Shares trades at $9.79. The key difference: Merck & Co., Inc. pays a 2.29% dividend while Direxion Daily TSLA Bull 2X Shares pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| MRK | TSLL | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $156.43 | $23.03 |
52-Week Low | $77.60 | $6.74 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
TSLL (Direxion Daily TSLA Bull 2X Shares ETF) trades at $9.87, up 7.87% on strong Tesla momentum ahead of the Cybercab event. The technical outlook is bullish with moving averages supporting upward momentum, while oscillators remain neutral. Recent news highlights investor enthusiasm for leveraged Tesla exposure, though the ETF's structure amplifies volatility risks.
The outlook remains driven by Tesla's performance, with potential upside from product launches but significant risk from daily rebalancing effects. Investors face amplified gains or losses relative to Tesla, requiring careful risk management given the ETF's leveraged structure and Tesla's inherent stock volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
